Contact the Editorial Desk

Editorial correspondence

Topical Peptides welcomes mail about the research record: a citation quoted inaccurately, a newly published trial on GHK-Cu, semaglutide, or thymosin alpha-1, or a regulatory change that shifts an approval status described here. Corrections of that kind are the most useful messages the bench receives, and each is read with care.

The most actionable notes name the page, quote the exact passage in question, and give a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be checked against its source before anything is altered.

Editorial mailbox: editors@topicalpeptides.com

What this desk cannot do

Topical Peptides is a reading bench, not a clinical service or a seller, so several things sit outside what it can do: it can't advise on or recommend human use of any peptide here, can't suggest a dose or schedule for anyone, can't judge whether a cited finding fits a particular person's situation, and can't help locate any compound from any supplier. It also can't guide anyone toward prescription medicines outside a licensed prescriber-patient relationship.

Semaglutide is a prescription medicine. Thymosin alpha-1 is approved abroad but investigational in the United States. GHK-Cu's topical, cosmetic form is legal and widely sold; other routes are unapproved and unstudied in humans. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Replies to editorial mail aren't guaranteed and may be delayed.